About Us

Our R&D team operates under the dual drivers of “addressing clinical urgency” and “global innovation,” supported by an AI-powered metabolic differentiation platform. We possess full-chain independent development capabilities spanning bioinformatics, structural design, CMC, pharmacological and toxicological research, patent studies, clinical research, and regulatory submissions. The team was recognized as: the 2021 Chengdu “Rong Piao Plan” Top Innovation and Entrepreneurship Team; and the 2022 “Tianfu Emei Plan” Entrepreneurship Team. Our core technical members have an average of over 20 years of experience in drug development , forming a high-tech talent matrix.